共 50 条
- [21] Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast CancerJOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) : 2698 - 2704Krop, Ian E.Beeram, MuralidharModi, ShanuJones, Suzanne F.Holden, Scott N.Yu, WeiGirish, SandhyaTibbitts, JayYi, Joo-HeeSliwkowski, Mark X.Jacobson, FredLutzker, Stuart G.Burris, Howard A.
- [22] Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Krop, Ian E.Masuda, NorikazuMukohara, ToruTakahashi, ShunjiNakayama, TakahiroInoue, KenichiIwata, HirojiToyama, TatsuyaYamamoto, YutakaHansra, Damien MikaelTakahashi, MasatoOsaki, AkihikoKoyama, KumikoInoue, TatsuyaYonekura, TakatoshiMostillo, JosephOhwada, ShoichiTanaka, YoshimiSternberg, David W.Yonemori, Kan
- [23] First-in-human phase I study of ALT-P7, a HER2-targeting antibody-drug conjugate in patients with HER2-positive advanced breast cancer.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Park, Yeon HeeAhn, Hee KyungKim, Ji-YeonAhn, Jin SeokIm, Young-HyuckKim, Seol-HeeLee, SunbaeChung, Hye-ShinPark, Soon Jae
- [24] Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutationJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Goetz, Matthew P.Wander, Seth AndrewBachelot, ThomasBatist, GeraldCortes, JavierCristofanilli, MassimoCurigliano, GiuseppeDe Nonneville, AlexandreGal-Yam, Einav NiliJhaveri, Komal L.Ma, Cynthia X.Parsons, Heather AnneRugo, Hope S.Sammons, Sarah L.Stover, Daniel G.Twelves, ChrisBardia, AdityaPlourde, Paul V.Portman, David JayDamodaran, Senthil
- [25] SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1/2 studySIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)Li, ZimingSong, ZhengboHong, WeiYang, NongWang, YongshengJian, HongLiang, ZibinHu, ShengPeng, MinYu, YanWang, YanJiao, ZicongZhao, KaijingSong, KeLi, YouShi, WeiLu, Shun
- [26] An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC)JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Bardia, AdityaO'Sullivan, Ciara CatherineMahtani, Reshma L.Blau, SibelAbdulla, Nihal E.Ali, AzkaBansal, RaniMeyer, Janelle MarieGeorge, Mridula AnnetteHan, Hyo S.Pluard, Timothy J.Papish, Steven W.Jones, Jason MichaelRong, YuanxinGao, GuozhiRugo, Hope S.
- [27] Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 studyLANCET ONCOLOGY, 2017, 18 (01) : 42 - 51Rudin, Charles M.Pietanza, M. CatherineBauer, Todd M.Ready, NealMorgensztern, DanielGlisson, Bonnie S.Byers, Lauren A.Johnson, Melissa L.Burris, Howard A., IIIRobert, FranciscoHan, Tae H.Bheddah, SheilaTheiss, NoahWatson, SkyMathur, DeepanVennapusa, BharathiZayed, HanyLally, SatwantStrickland, Donald K.Govindan, RamaswamyDylla, Scott J.Peng, Stanford L.Spigel, David R.
- [28] A phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-positive, unresectable and/or metastatic breast cancer previously treated with T-DM1.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Baselga, JoseTamura, KenjiYamashita, ToshinariModi, ShanuTokunaga, ErikoIto, YoshinoriIwata, HirojiCharif, MahmoudLee, Caleb C.Sugihara, MasahiroJikoh, TakahiroAndre, Fabrice
- [29] A FIRST IN-HUMAN, MULTICENTER, OPEN-LABEL, DOSE-FINDING PHASE 1 STUDY OF THE IMMUNE STIMULATOR ANTIBODY CONJUGATE NJH395 IN PATIENTS WITH NONBREAST HER2+ADVANCED MALIGNANCIESJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A230 - A230Janku, FilipHan, Sae-WonDoi, ToshihikoAjani, JafferKuboki, YasutoshiMahling, PingSubramanian, KulandayanPelletier, MarcAskoxylakis, VasileiosSiena, Salvatore
- [30] Trial in progress: Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating locally advanced or ER+/HER2-metastatic breast cancer with an ESR1 mutationCANCER RESEARCH, 2024, 84 (09)Goetz, MatthewWander, SethBachelot, ThomasBatist, GeraldCortes, JavierCristofanilli, MassimoCurigliano, Giuseppede Nonneville, AlexandreYam, Einav Nili-GalJhaveri, KomalMa, CynthiaParsons, HeatherRugo, HopeSammons, SarahStover, DanielTwelves, ChrisBardia, AdityaPlourde, Paul V.Portman, David J.Damodaran, Senthil